Popular Articles

Risk For Premature Birth May Be Heightened By Pre-Pregnancy Depressed Mood
Researchers trying to uncover why premature birth is a growing problem in the United States and one that disproportionately affects black women have found that pre-pregnancy depressive mood appears to be a risk factor in preterm birth among both blacks and whites.
generic viagra online
Novel Role Of Gene May Provide Key To Treating Liver And Neurodegenerative Diseases
Scientists at Singapore"s Bioprocessing Technology Institute (BTI) have made a novel discovery about how the gene, "Fas-apoptosis inhibitory molecule" (FAIM), protects both immune and liver cells from apoptosis, or programmed cell death.
News of the day
New York Becomes First State To Allow Payment For Donating Eggs For Stem Cell Research
New York"s Empire State Stem Cell Board earlier this month decided to allow embryonic stem cell researchers who receive state funding to compensate women for donating their eggs for use in research, making New York the first state to enact such a policy, the Washington Post reports (Stein, Washington Post, 6/26). According to the New York Times, the New York state Legislature in 2007 allotted $600 million for an 11-year stem cell research plan (Nelson, New York Times, 6/26). Under the board"s decisions, researchers receiving the state funding may pay women up to $10,000 to compensate them for the time, discomfort and expenses associated with egg donation. David Hohn, vice chair of the board"s two committees that endorsed the decision, said that the board "could not distinguish ethically between the payment for in vitro fertilization, which is very well precedented, and the compensation for donation for research." The board said researchers should follow the same guidelines as infertility clinics that receive donated eggs for infertile couples. Under those guidelines, payments exceeding $5,000 must be justified, and those exceeding $10,000 are considered excessive (Washington Post, 6/26). Robert Klitzman, director of the master"s degree program in bioethics at Columbia University and a member of the stem cell board"s ethics committee, said the payments will be carefully evaluated by an institutional review board (New York Times, 6/26).The Post reports that the decision goes against policies in other states that offer funding for embryonic stem cell research, as well as against current guidelines from scientific organizations like the National Academy of Sciences (Washington Post, 6/26). NAS guidelines, for example, prohibit paying women for eggs used in stem cell research. Similarly, the internal guidelines for New York-based groups like Rockefeller University, Cornell University and the Sloan-Kettering Institute prohibit financial compensation for donated eggs. However, researchers say that efforts to recruit unpaid donors have been unsuccessful and that the board"s decision will give New York an advantage in stem cell research (New York Times, 6/26). The decision was welcomed by scientists and other proponents of stem cell research, who said it will allow them to further research in areas like therapeutic cloning. The process, also known as somatic cell nuclear transfer, involves replacing the genetic material in a human egg with genes from the nucleus of a patient"s cell. The egg is then developed into an early embryo, which, in theory, could be used to produce stem cells that the patient"s immune system would not reject. Although the procedure has been unsuccessful so far, researchers say the board"s decision will help attract more donors, which will allow for more experiments. Egg donation involves weeks of hormone injections to stimulate the ovaries and a painful egg extraction procedure, which carries rare but serious risks. Other attempts at soliciting women to donate eggs for stem cell research have been unsuccessful, according to the Post.Some critics of the board"s decision said that paying women for eggs could lead to exploitation, especially for low-income women. Thomas Berg -- a Roman Catholic priest who is director of the Westchester Institute for Ethics and the Human Person and a member of the Empire State Stem Cell Board"s ethics committee -- said that in the current economic recession, paying a woman $10,000 to participate in a research project is an "undue inducement." He added that he thinks it "manipulates women" and "creates a trafficking in human body parts." Other opponents of the decision questioned if compensating women who donate eggs for research is indeed equivalent to the process for infertility treatments. Jonathan Moreno, a professor of bioethics at the University of Pennsylvania, said that donors recognize that egg donation for infertility treatments is a "very concrete good for society" but that "you can"t be sure any biological material you collect for research wi
Sexual Health

Agendia Opens CLIA-Registered U.S. Genomics Laboratory

Agendia, a world leader in molecular cancer diagnostics, announced the opening of its U.S. clinical genomics laboratory in Huntington Beach, CA. The laboratory is fully-licensed and compliant with the Clinical Laboratory Improvements Amendments (CLIA) as administered by the Centers for Medicare and Medicaid Services (CMS). In addition to opening its U.S. cancer genomics laboratory, Agendia has over the past months made several key additions to its domestic-based senior executive team. The team consists of Dr. Richard Bender, Chief Medical Officer, Mr. Daniel Forche, Vice President of Sales & Marketing, Mr. Alan B. Carter, Vice President of Global Business Development, and pathologist Dr. Chynel Henning, Laboratory Director. "Our new genomics lab"s capacity will allow us to meet the increasing demand for MammaPrint across the United States and give physicians and patients optimal test result turnaround and unmatched service and support," noted Jan Groen, Ph.D., Chief Operating Officer. "This expansion places us in an excellent position to continue making advancements in molecular cancer diagnostics and equip oncologists with powerful tools to use in the fight against breast cancer." Dr. Bernhard Sixt, President and Chief Executive Officer, added, "the opening of the Huntington Beach laboratory and the appointment of our U.S.-based commercial team provide a strong basis for our U.S. operations and for Agendia"s next phase of growth. Our enhanced domestic capabilities will help us to further drive adoption of MammaPrint, and place us in an even better position to collaborate with a growing number of clinical, academic, and industrial partners here in the U.S." Dr. Bender has more than 30 years of medical and professional experience as a practicing oncologist and director of several oncology programs. Dr. Bender has served as Medical Director of the Hematology/Oncology Program at Quest Diagnostics, Director of Medical Oncology and Hematology at Kaiser Permanente Medical Group, Director of Strategic Development in Medical Oncology/Hematology at Johnson & Johnson, and as an investigator at the National Cancer Institute and Scripps Clinic and Research Foundation. Currently, Dr. Bender serves as an expert reviewer in oncology for the Medical Board of California, co-Editor of Anti-Cancer Drugs, an international journal on anti-cancer agents, and as a clinical instructor in medicine at the University of California, Irvine School of Medicine. Mr. Forche brings more than 18 years of sales, marketing and commercial leadership experience in the diagnostics arena. Prior to joining Agendia, Mr. Forche was the Senior Vice President of Sales and Marketing for Insight Health Corporation, a national leader in diagnostic imaging services. He also served as Vice President of Marketing at US LABS, an industry leader in cancer diagnostic and genomic testing services, and has held sales and marketing management roles at Ventana Medical Systems (now Roche) and Abbott Laboratories. Mr. Carter joins Agendia with 25 years of global business development experience from a number of top-tier life sciences companies such as BioTrove, Celera, Applied Biosystems, and Perkin Elmer. At Agendia, he oversees ongoing strategic alliances within the bio-pharmaceutical sector and collaboration with partners interested in Agendia"s expanding molecular diagnostics portfolio. Chynel Henning, M.D., Ph.D., FASCP, FCAP, joins Agendia with more than 30 years of experience as a laboratory director. He is currently also Director of National Cyto-Path Laboratories and Professional Pathology Medical Group Laboratory, both in Long Beach, California; and Director of the Laboratory and Department of Pathology at the Miracle Mile Medical Center, Los Angeles. Dr. Henning is a Fellow of the American Society of Clinical Pathologists and the College of American Pathologists. Ongoing research and development commitments continue to augment Agendia"s ability to accurately predict breast cancer recurrence and sub-typing, and help physicians tailor individual treatment plans to their patients. Agendia"s goal is to provide women with answers to crucial treatment questions, such as how their breast cancer will respond to targeted therapies or various chemotherapy regimens. Agendia B.V.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):